Intranasal Vaccination with Recombinant Adeno-associated Virus Type 5 Against Human Papillomavirus Type 16 L1

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2006 Feb 28

PMID 16501072

Citations 28

Authors

Dirk Kuck

Tobias Lau

Barbara Leuchs

Andrea Kern

Martin Muller

Lutz Gissmann

Jurgen A Kleinschmidt

Affiliations

Soon will be listed here.

Abstract

Adeno-associated viruses (AAV) have been developed and evaluated as recombinant vectors for gene therapy in many preclinical studies, as well as in clinical trials. However, only a few approaches have used recombinant AAV (rAAV) to deliver vaccine antigens. We generated an rAAV encoding the major capsid protein L1 (L1h) from the human papillomavirus type 16 (HPV16), aiming to develop a prophylactic vaccine against HPV16 infections, which are the major cause of cervical cancer in women worldwide. A single dose of rAAV5 L1h administered intranasally was sufficient to induce high titers of L1-specific serum antibodies, as well as mucosal antibodies in vaginal washes. Seroconversion was maintained for at least 1 year. In addition, a cellular immune response was still detectable 60 weeks after immunization. Furthermore, lyophilized rAAV5 L1h successfully evoked a systemic and mucosal immune response in mice. These data clearly show the efficacy of a single-dose intranasal immunization against HPV16 based on the recombinant rAAV5L1h vector without the need of an adjuvant.

Citing Articles

Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.

Amiri S, Rasekh S, Moezzi S, Seifi N, Fatemi S, Fathi S Infect Agent Cancer. 2025; 20(1):16.

PMID: 40059217 PMC: 11892266. DOI: 10.1186/s13027-025-00643-5.

A novel platform for engineered AAV-based vaccines.

Babutzka S, Gehrke M, Papadopoulou A, Diedrichs-Mohring M, Giannaki M, Hennis L Mol Ther Methods Clin Dev. 2025; 33(1):101418.

PMID: 40008090 PMC: 11850754. DOI: 10.1016/j.omtm.2025.101418.

Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines.

Filipic B, Pantelic I, Nikolic I, Majhen D, Stojic-Vukanic Z, Savic S Vaccines (Basel). 2023; 11(7).

PMID: 37514991 PMC: 10385383. DOI: 10.3390/vaccines11071172.

The use of viral vectors in vaccine development.

Travieso T, Li J, Mahesh S, Mello J, Blasi M NPJ Vaccines. 2022; 7(1):75.

PMID: 35787629 PMC: 9253346. DOI: 10.1038/s41541-022-00503-y.

Recombinant adeno-associated virus serotype 9 AAV-RABVG expressing a Rabies Virus G protein confers long-lasting immune responses in mice and non-human primates.

Shi C, Tian L, Zheng W, Zhu Y, Sun P, Liu L Emerg Microbes Infect. 2022; 11(1):1439-1451.

PMID: 35579916 PMC: 9154782. DOI: 10.1080/22221751.2022.2078226.

References

Bessis N, GarciaCozar F, Boissier M . Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004; 11 Suppl 1:S10-7. DOI: 10.1038/sj.gt.3302364. View

Blacklow N, HOGGAN M, Kapikian A, Austin J, Rowe W . Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol. 1968; 88(3):368-78. DOI: 10.1093/oxfordjournals.aje.a120897. View

SPRECHER-GOLDBERGER S, THIRY L, Lefebvre N, Dekegel D, de Halleux F . Complement-fixation antibodies to adenovirus-associated viruses, cytomegaloviruses and herpes simplex viruses in patients with tumors and in control individuals. Am J Epidemiol. 1971; 94(4):351-8. DOI: 10.1093/oxfordjournals.aje.a121330. View

Mayor H, Drake S, Stahmann J, Mumford D . Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol. 1976; 126(1):100-4. DOI: 10.1016/0002-9378(76)90472-5. View

Biederlack S, Wolf J, zur Hausen H . Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology. 1984; 134(1):64-71. DOI: 10.1016/0042-6822(84)90272-1. View

McLean C, Churcher M, Meinke J, Smith G, Higgins G, Stanley M . Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol. 1990; 43(6):488-92. PMC: 502503. DOI: 10.1136/jcp.43.6.488. View

Zabner J, Seiler M, Walters R, Kotin R, Fulgeras W, Davidson B . Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol. 2000; 74(8):3852-8. PMC: 111893. DOI: 10.1128/jvi.74.8.3852-3858.2000. View

Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Muller M, Zhou J, Gissmann L . Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine. 2000; 19(2-3):227-33. DOI: 10.1016/s0264-410x(00)00173-0. View

Harro C, Pang Y, Roden R, Hildesheim A, Wang Z, Reynolds M . Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001; 93(4):284-92. DOI: 10.1093/jnci/93.4.284. View

10.

Kawana Y, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T . Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol. 2001; 75(5):2331-6. PMC: 114816. DOI: 10.1128/JVI.75.5.2331-2336.2001. View

11.

Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T . Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine. 2001; 19(11-12):1496-502. DOI: 10.1016/s0264-410x(00)00367-4. View

12.

Kaufmann A, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H . HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer. 2001; 92(2):285-93. DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1181>3.0.co;2-q. View

13.

Xin K, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K . A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther. 2001; 12(9):1047-61. DOI: 10.1089/104303401750214276. View

14.

Leder C, Kleinschmidt J, WIETHE C, Muller M . Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol. 2001; 75(19):9201-9. PMC: 114488. DOI: 10.1128/JVI.75.19.9201-9209.2001. View

15.

Johansson E, Wassen L, Holmgren J, Jertborn M, Rudin A . Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 2001; 69(12):7481-6. PMC: 98837. DOI: 10.1128/IAI.69.12.7481-7486.2001. View

16.

Walters R, Pilewski J, Chiorini J, Zabner J . Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem. 2002; 277(26):23709-13. DOI: 10.1074/jbc.M200292200. View

17.

Brockstedt D, Podsakoff G, Fong L, Kurtzman G, MUELLER-RUCHHOLTZ W, Engleman E . Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999; 92(1):67-75. DOI: 10.1006/clim.1999.4724. View

18.

Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidt J . Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 1999; 6(7):1322-30. DOI: 10.1038/sj.gt.3300946. View

19.

Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J . Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999; 6(9):1574-83. DOI: 10.1038/sj.gt.3300994. View

20.

Erles K, Sebokova P, Schlehofer J . Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999; 59(3):406-11. DOI: 10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n. View